NCT07348484
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
At risk: Primary completion moved at least 3 months later.
See at-risk trials from Instituto de Investigación Biomédica de Salamanca
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 7 more changesShow less
- Eligibility criteria expanded, about 8 words
- Primary completion pushed from Dec 2027 to Apr 2028
- Study completion pushed from Mar 2028 to Dec 2028
- Start date changed from estimate of Jan 2026 to Apr 1, 2026
- Secondary endpoints: details revised at 6 of 13 entries
- Site details revised
- Study description expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety.
Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up. These patients receive standard clinical care according to local and national guidelines. They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems. Reasons for non-initiation of SGLT2i are documented systematically and may include: Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio \<200 mg/g, eGFR \<20 mL/min/1.73 m² for empagliflozin or \<25 for dapagliflozin), or Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity. Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over).
Drugs: Empagliflozin
Sites
1 site in 1 country
- Hospital Universitario de SalamancaSalamanca, Spain